DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
NEW YORK, March 02, 2016 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the upcoming 36th Annual Cowen & Company Global Healthcare Conference, and the 28th Annual ROTH Conference.
| 36th Annual Cowen & Company Global Healthcare Conference | |||||
| Date: | Monday, March 7 | ||||
| Time: | 3:20pm Eastern Time | ||||
| Location: | Salon C, Boston Marriott Copley Place, Boston, MA | ||||
| Webcast: | http://wsw.com/webcast/cowen30/ohrp | ||||
| 28th Annual ROTH Conference | |||||
| Date: | Tuesday, March 15 | ||||
| Time: | 3:00pm Pacific Time | ||||
| Location: | Salon 2 Blue, The Ritz Carlton Hotel, Dana Point | ||||
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. LifeSci Advisors, LLC Investor Relations Michael Wood 888-388-2327 646-597-6983 [email protected] [email protected]
